MannKind Corporation (MNKD)’s Run to Glory

Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year. The value of the biotech is up a whopping 584% when you look at the company’s market cap because of all the additional shares it’s sold.

MNKD Chart

MannKind data by YCharts.

What’s caused this increase?
Increased revenue? Nope, MannKind Corporation (NASDAQ:MNKD) doesn’t have any products for sale.

Clinical trial data? Not really. The company completed enrollment for two phase 3 trials testing its inhaled insulin Afrezza in October, but the trials aren’t expected to read out until this summer.

MannKind Corporation (NASDAQ:MNKD)Big licensing deal? No, MannKind Corporation (NASDAQ:MNKD) has been talking about one for years, but nothing has materialized yet.

Instead, it looks like the price increase is simply because investors are more interested in owning MannKind than they were a year ago. More buyers and fewer sellers means the price has to go up. Valuation be damned.

Why now?
It’s the typical run-up that biotechs see before data will be released or before the Food and Drug Administration is scheduled to make a decision about a marketing application. In MannKind Corporation (NASDAQ:MNKD)’s case, it’s those phase 3 trials that are being wrapped up and should report shortly.

With no binary event in the foreseeable future — and for some traders, foreseeable can be a month, often less — few investors want to own a biotech as it’s unlikely to change in value with no news. As the binary event approaches, more people want to own the company, which drives the shares higher.

Priced in
The problem with this run up, especially for events like MannKind Corporation (NASDAQ:MNKD)’s phase 3 trials that are widely expected to be positive, is that most of the upside is already gone.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), for instance, fell more than 20% after receiving FDA approval for its leukemia drug Iclusig. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had more than doubled from the year before as it ran up to the decision. Shares still haven’t recovered to their pre-run-up level. Binary event traders have moved on. To add to its $3.6 billion valuation from here, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is going to have to do it the old-fashioned way: increasing sales.

There’s risk that, even with good data, we could see the same issue for MannKind Corporation (NASDAQ:MNKD). Unless the company signs a big marketing partnership, investors are going to be rightfully worried about the launch of Afrezza after Pfizer Inc. (NYSE:PFE)‘s flop with its inhaled insulin, Exubera, a few years ago. Afrezza is arguably a much better product than Exubera, but MannKind is still going to have the same problem Pfizer Inc. (NYSE:PFE) had; invoking a paradigm shift on how doctors treat diabetics that need insulin isn’t easy and will require a lot of marketing muscle.

The article MannKind’s Run to Glory originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!